Project Grant R01HL180496
Award Date 8/15/26
Completion Date 5/31/31
Dollars Obligated $350K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Providence, RI 02912, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Brown University $801,800 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to evaluate the Health Zones Initiative, a statewide community intervention model in Rhode Island designed to improve diet quality, physical activity, and cardiovascular disease outcomes across 14 communities. The project will assess the effectiveness, implementation, and interaction between implementation and effectiveness of the...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $908,994 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test implementation strategies for electronic health record-based interventions to improve hypertension control in primary care settings. The project builds on the recipient's prior NIH-funded REDUCE-BP trial, which enrolled 49,210 patients and 560 primary care providers and demonstrated that multi-component...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Brigham & Women's Hospital Inc. $1.789 million on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds integrative computational-experimental approaches to identify rare coding variants that influence lipid metabolism and cardiovascular disease risk. The research combines large-scale population cohort data with high-throughput functional screening using base and prime...
- The National Heart, Lung, and Blood Institute of the Department of Health and Human Services awarded Duke University $1,532,545 on June 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to analyze the effect of income-based health insurance benefit designs on cardiovascular disease outcomes and disparities among low-income workers. The research examines whether employers' selective provision of more generous health benefits—such as free cardioprotective medicines or low...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $849,790 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode regulatory variants in cardiovascular disease through functional annotation of non-coding variants associated with CVD. The recipient will characterize non-coding regulatory variants and their mechanisms using high-throughput experimental approaches in human cardiomyocytes. Aim 1 encompasses biophysical...
- The National Heart, Lung, and Blood Institute awarded Endeavor Health Clinical Operations $1,553,928 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate equilibrium phase BT1RESS MR angiography for improved cardiovascular imaging. The award funds a five-year technical development and clinical validation program testing a magnetization-prepared, ECG-gated balanced steady-state free precession pulse sequence that enables high-quality...
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $685,212 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop policy-relevant evidence on the scope and effects of prior authorization (PA) for cardiovascular care. The project quantifies patient exposure to PA for cardiovascular services from 2016 through 2024, identifying which patient groups experience PA barriers and measuring how PA affects service use, care...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $249,000 on March 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct genomic and functional molecular analyses investigating the mechanistic links between clonal hematopoiesis of indeterminate potential (CHIP) and coronary artery disease (CAD). The recipient will discover further germline genetic predisposition that induces CHIP-related cardiovascular disease using an...
- The National Heart Lung and Blood Institute awarded Brigham & Womens Hospital Inc. $167,400 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant K08HL183779). The award funds a translational research program evaluating the differential biology and risk factors between atherogenic and non-atherogenic calcific aortic valve disease. Research aims include: (1) using multi-trait human genetics to distinguish atherogenic and non-atherogenic genetic...
- The National Heart, Lung, and Blood Institute awarded Rhode Island Hospital $712,858 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of DELTEX E3 ubiquitin ligase 3L (DTX3L) in sepsis-induced insulin resistance and cardiac dysfunction. The research examines whether muscle-specific DTX3L mediates ubiquitination and degradation of HDAC4 as a mechanism to mitigate septic cardiac depression and insulin resistance. The project uses...